0.61  -0.041 (-6.3%)		12-12 16:00
Open: 0.63 High: 0.6499 Volume: 306,471		Pre. Close: 0.651 Low: 0.5903 Market Cap: 59(M)

Short term
Mid term
Targets	6-month :	0.83	1-year :	0.98
Resists	First :	0.71	Second :	0.83
Pivot price	0.65
Supports	First :	0.51	Second :	0.43
MAs	MA(5) :	0.61	MA(20) :	0.66
	MA(100) :	0.66	MA(250) :	0.75
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	29.4	D(3) :	27.3
RSI	RSI(14): 45
52-week	High :	1.23	Low :	0.43

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ VNRX ] has closed above bottom band by 34.6%. Bollinger Bands are 31.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.65 - 0.65	0.65 - 0.66
Low:	0.58 - 0.59	0.59 - 0.59
Close:	0.6 - 0.61	0.61 - 0.61

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.

Thu, 12 Dec 2024
VolitionRx Strengthens Market Presence: Partners with LifeSci Advisors Following Major Product Launch - StockTitan

Tue, 10 Dec 2024
VolitionRx chief scientific officer Micallef acquires $24,999 in stock - Investing.com

Tue, 10 Dec 2024
VolitionRx CEO Cameron John Reynolds acquires $79,999 in stock - Investing.com

Tue, 10 Dec 2024
VolitionRx's Nu.Q® Cancer Test Shows 92% Accuracy in Groundbreaking Lung Cancer Study - StockTitan

Mon, 09 Dec 2024
SEC Form 424B5 filed by VolitionRX Limited - Quantisnow

Mon, 09 Dec 2024
VolitionRx announces pricing of up to $1.9M registered direct offering - MSN

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Shares Out	0 (M)
Shares Float	92 (M)
Held by Insiders	7.257e+007 (%)
Held by Institutions	21.4 (%)
Shares Short	382 (K)
Shares Short P.Month	0 (K)

EPS	-3.164e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-1 %
Return on Assets (ttm)	766.1 %
Return on Equity (ttm)	-100.9 %
Qtrly Rev. Growth	976520 %
Gross Profit (p.s.)	74.77
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	-0.5 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-17 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	-2.61

Dividend	0
Forward Dividend	448930
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.